ID   SMS-KCN
AC   CVCL_7133
SY   KCN; SMS-KCNs; NB07C
DR   BTO; BTO:0003548
DR   CGH-DB; 71-1
DR   CGH-DB; 9091-4
DR   Cosmic; 717426
DR   Cosmic; 848940
DR   Cosmic; 923827
DR   Cosmic; 1019932
DR   Cosmic; 1162007
DR   Cosmic; 1890077
DR   Cosmic; 2393632
DR   GEO; GSM3145730
DR   Wikidata; Q54954990
RX   DOI=10.1007/0-306-46872-7_2;
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RX   PubMed=2019470;
RX   PubMed=2535691;
RX   PubMed=3456456;
RX   PubMed=7037175;
RX   PubMed=12702577;
RX   PubMed=15150091;
RX   PubMed=15720811;
RX   PubMed=15892104;
RX   PubMed=16822308;
RX   PubMed=18724359;
RX   PubMed=23202128;
RX   PubMed=24792489;
RX   PubMed=25884760;
RX   PubMed=26342562;
WW   http://www.cccells.org/dl/NB_Data_Sheets/SMS-KCN_Cell_Line_Data_Sheet_COGcell_org.pdf
CC   Characteristics: Substrate-adherent type (S-type) (PubMed=15720811).
CC   Doubling time: ~109 hours (PubMed=3456456).
CC   Sequence variation: Mutation; HGNC; 427; ALK; Simple; p.Arg1275Gln (c.3824G>A); ClinVar=VCV000018083; Zygosity=Unspecified (PubMed=18724359).
CC   Omics: Array-based CGH.
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: Deep tyrosine phosphoproteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: Transcriptome analysis.
ST   Source(s): COG
ST   Amelogenin: X,Y
ST   CSF1PO: 10
ST   D13S317: 12,13
ST   D16S539: 10,11
ST   D18S51: 15,19
ST   D19S433: 14,15
ST   D21S11: 30,31.2
ST   D2S1338: 17,22
ST   D3S1358: 14,15
ST   D5S818: 11
ST   D7S820: 9,11
ST   D8S1179: 13,14
ST   FGA: 19,22
ST   TH01: 9.3
ST   TPOX: 11
ST   vWA: 17,18
DI   NCIt; C3270; Neuroblastoma
DI   ORDO; Orphanet_635; Neuroblastoma
OX   NCBI_TaxID=9606; ! Homo sapiens
OI   CVCL_AQ28 ! SMS-KCL
OI   CVCL_7134 ! SMS-KCNR
SX   Male
AG   11M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 23-06-22; Version: 23
//
RX   DOI=10.1007/0-306-46872-7_2;
RA   Thiele C.J.;
RT   "Neuroblastoma.";
RL   (In) Human cell culture. Vol. 1. Cancer Cell Lines part 1; Masters J.R.W., Palsson B.O. (eds.); pp.21-53; Kluwer Academic Publishers; New York (1999).
//
RX   DOI=10.1016/B978-0-12-333530-2.50006-X;
RA   Israel M.A., Thiele C.J.;
RT   "Tumor cell lines of the peripheral nervous system.";
RL   (In) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.43-78; Academic Press; New York (1994).
//
RX   PubMed=2019470; DOI=10.1002/ijc.2910480221;
RA   Sugimoto T., Ueyama H., Hosoi H., Inazawa J., Kato T., Kemshead J.T.,
RA   Reynolds C.P., Gown A.M., Mine H., Sawada T.;
RT   "Alpha-smooth-muscle actin and desmin expressions in human
RT   neuroblastoma cell lines.";
RL   Int. J. Cancer 48:277-283(1991).
//
RX   PubMed=2535691;
RA   Ciccarone V., Spengler B.A., Meyers M.B., Biedler J.L., Ross R.A.;
RT   "Phenotypic diversification in human neuroblastoma cells: expression
RT   of distinct neural crest lineages.";
RL   Cancer Res. 49:219-225(1989).
//
RX   PubMed=3456456; DOI=10.1093/jnci/76.3.375;
RA   Reynolds C.P., Biedler J.L., Spengler B.A., Reynolds D.A., Ross R.A.,
RA   Frenkel E.P., Smith R.G.;
RT   "Characterization of human neuroblastoma cell lines established before
RT   and after therapy.";
RL   J. Natl. Cancer Inst. 76:375-387(1986).
//
RX   PubMed=7037175;
RA   Reynolds C.P., Reynolds D.A., Frenkel E.P., Smith R.G.;
RT   "Selective toxicity of 6-hydroxydopamine and ascorbate for human
RT   neuroblastoma in vitro: a model for clearing marrow prior to
RT   autologous transplant.";
RL   Cancer Res. 42:1331-1336(1982).
//
RX   PubMed=12702577;
RA   Saito-Ohara F., Imoto I., Inoue J., Hosoi H., Nakagawara A.,
RA   Sugimoto T., Inazawa J.;
RT   "PPM1D is a potential target for 17q gain in neuroblastoma.";
RL   Cancer Res. 63:1876-1883(2003).
//
RX   PubMed=15150091; DOI=10.1158/0008-5472.CAN-03-0809;
RA   Schaefer K.-L., Brachwitz K., Wai D.H., Braun Y., Diallo R.,
RA   Korsching E., Eisenacher M., Voss R., van Valen F., Baer C., Selle B.,
RA   Spahn L., Liao S.-K., Lee K.A.W., Hogendoorn P.C.W., Reifenberger G.,
RA   Gabbert H.E., Poremba C.;
RT   "Expression profiling of t(12;22) positive clear cell sarcoma of soft
RT   tissue cell lines reveals characteristic up-regulation of potential
RT   new marker genes including ERBB3.";
RL   Cancer Res. 64:3395-3405(2004).
//
RX   PubMed=15720811; DOI=10.1593/neo.04310;
RA   Walton J.D., Kattan D.R., Thomas S.K., Spengler B.A., Guo H.-F.,
RA   Biedler J.L., Cheung N.-K.V., Ross R.A.;
RT   "Characteristics of stem cells from human neuroblastoma cell lines and
RT   in tumors.";
RL   Neoplasia 6:838-845(2004).
//
RX   PubMed=15892104; DOI=10.1002/gcc.20198;
RA   Mosse Y.P., Greshock J., Margolin A.A., Naylor T., Cole K., Khazi D.,
RA   Hii G., Winter C., Shahzad S., Asziz M.U., Biegel J.A., Weber B.L.,
RA   Maris J.M.;
RT   "High-resolution detection and mapping of genomic DNA alterations in
RT   neuroblastoma.";
RL   Genes Chromosomes Cancer 43:390-403(2005).
//
RX   PubMed=16822308; DOI=10.1186/1471-2407-6-177;
RA   Dam V., Morgan B.T., Mazanek P., Hogarty M.D.;
RT   "Mutations in PIK3CA are infrequent in neuroblastoma.";
RL   BMC Cancer 6:177.1-177.10(2006).
//
RX   PubMed=18724359; DOI=10.1038/nature07261;
RA   Mosse Y.P., Laudenslager M., Longo L., Cole K.A., Wood A.,
RA   Attiyeh E.F., Laquaglia M.J., Sennett R., Lynch J.E., Perri P.,
RA   Laureys G., Speleman F., Kim C., Hou C.-P., Hakonarson H., Torkamani A.,
RA   Schork N.J., Brodeur G.M., Tonini G.P., Rappaport E., Devoto M.,
RA   Maris J.M.;
RT   "Identification of ALK as a major familial neuroblastoma
RT   predisposition gene.";
RL   Nature 455:930-935(2008).
//
RX   PubMed=23202128; DOI=10.1038/ng.2493;
RA   Sausen M., Leary R.J., Jones S., Wu J., Reynolds C.P., Liu X.-Y.,
RA   Blackford A.L., Parmigiani G., Diaz L.A. Jr., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E., Hogarty M.D.;
RT   "Integrated genomic analyses identify ARID1A and ARID1B alterations in
RT   the childhood cancer neuroblastoma.";
RL   Nat. Genet. 45:12-17(2013).
//
RX   PubMed=24792489; DOI=10.1007/s11060-014-1456-8;
RA   Farooqi A.S., Dagg R.A., Choi L.M.R., Shay J.W., Reynolds C.P.,
RA   Lau L.M.S.;
RT   "Alternative lengthening of telomeres in neuroblastoma cell lines is
RT   associated with a lack of MYCN genomic amplification and with p53
RT   pathway aberrations.";
RL   J. Neurooncol. 119:17-26(2014).
//
RX   PubMed=25884760; DOI=10.1371/journal.pcbi.1004130;
RA   Palacios-Moreno J., Foltz L., Guo A.-L., Stokes M.P., Kuehn E.D.,
RA   George L., Comb M.J., Grimes M.L.;
RT   "Neuroblastoma tyrosine kinase signaling networks involve FYN and LYN
RT   in endosomes and lipid rafts.";
RL   PLoS Comput. Biol. 11:e1004130.1-e1004130.33(2015).
//
RX   PubMed=26342562; DOI=10.1016/j.scr.2015.08.008;
RA   Ross R.A., Walton J.D., Han D., Guo H.-F., Cheung N.-K.V.;
RT   "A distinct gene expression signature characterizes human
RT   neuroblastoma cancer stem cells.";
RL   Stem Cell Res. 15:419-426(2015).
//